07:35 AM EDT, 10/20/2025 (MT Newswires) -- Autolus Therapeutics ( AUTL ) said Monday that the first patient has dosed in its phase 1 trial of obecabtagene autoleucel to treat progressive multiple sclerosis.

The patient was treated at University College London Hospitals NHS Foundation Trust, the company said.

The trial will enroll up to 18 adult patients with refractory progressive forms of multiple sclerosis, the company said, adding that the study will evaluate the safety, tolerability, and preliminary efficacy of obe-cel.

Shares of Autolus Therapeutics ( AUTL ) were 11% higher in premarket trading.